Co-Authors
This is a "connection" page, showing publications co-authored by BANU K ARUN and HELEN PIWNICA-WORMS.
Connection Strength
0.455
-
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
Score: 0.181
-
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer. 2017; 3:49.
Score: 0.161
-
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
Score: 0.058
-
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment na?ve gBRCA+ breast cancers. NPJ Breast Cancer. 2022 May 10; 8(1):64.
Score: 0.055